Li Muzi, Zhao Xiangyu
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
Chin Med J (Engl). 2024 Nov 20;137(22):2697-2711. doi: 10.1097/CM9.0000000000003195. Epub 2024 Jul 8.
Leukocyte immunoglobulin-like receptor (LILR) B4 (also known as ILT3/CD85k) is an immune checkpoint protein that is highly expressed in solid tumors and hematological malignancies and plays a significant role in the pathophysiology of cancer. LILRB4 is highly expressed in acute myeloid leukemia (AML), and this phenotype is associated with adverse patient outcomes. Its differential expression in tumors compared to normal tissues, its presence in tumor stem cells, and its multifaceted roles in tumorigenesis position it as a promising therapeutic target in AML. Currently, several immunotherapies targeting LILRB4 are undergoing clinical trials. This review summarizes advancements made in the study of LILRB4 in AML, focusing on its structure, ligands, expression, and significance in normal tissues and AML; its protumorigenic effects and mechanisms in AML; and the application of LILRB4-targeted therapies in AML. These insights highlight the potential advantages of LILRB4 as an immunotherapeutic target in the context of AML.
白细胞免疫球蛋白样受体（LILR）B4（也称为ILT3/CD85k）是一种免疫检查点蛋白，在实体瘤和血液系统恶性肿瘤中高度表达，在癌症的病理生理学中起重要作用。LILRB4在急性髓系白血病（AML）中高度表达，这种表型与患者的不良预后相关。与正常组织相比，其在肿瘤中的差异表达、在肿瘤干细胞中的存在以及在肿瘤发生中的多方面作用使其成为AML中一个有前景的治疗靶点。目前，几种靶向LILRB4的免疫疗法正在进行临床试验。本综述总结了AML中LILRB4研究的进展，重点关注其结构、配体、在正常组织和AML中的表达及意义；其在AML中的促肿瘤作用和机制；以及LILRB4靶向疗法在AML中的应用。这些见解突出了LILRB4作为AML免疫治疗靶点的潜在优势。
